Applied DNA Sciences Files Amendment to S-1 Registration Statement

TL;DR

<b>Applied DNA Sciences filed an S-1/A amendment for securities registration, indicating an upcoming public offering.</b>

AI Summary

APPLIED DNA SCIENCES INC (BNBX) filed a Amended IPO Registration (S-1/A) with the SEC on May 15, 2024. Applied DNA Sciences, Inc. filed an amendment (S-1/A) to its registration statement on May 15, 2024. The filing is registered under the Securities Act of 1933 with registration number 333-278890. The company's principal executive offices are located at 50 Health Sciences Drive, Stony Brook, New York. James A. Hayward, Ph.D., Sc.D. is the Chairman, Chief Executive Officer, and President. The filing indicates the proposed sale of securities will commence as soon as practicable after the registration statement becomes effective.

Why It Matters

For investors and stakeholders tracking APPLIED DNA SCIENCES INC, this filing contains several important signals. This S-1/A filing is a crucial step in the company's process to offer new securities to the public, which could provide capital for operations or expansion. The amendment suggests potential adjustments or updates to the initial registration statement, which investors should review for the latest details on the offering and company status.

Risk Assessment

Risk Level: low — APPLIED DNA SCIENCES INC shows low risk based on this filing. The filing is an S-1/A amendment, which is a procedural step in registering securities and does not contain new financial performance data or significant business updates that would alter the risk profile.

Analyst Insight

Review the full S-1/A filing for any updated details regarding the securities offering, potential use of proceeds, and any revised risk factors.

Key Numbers

• 2024-05-15 — Filing Date (Date of S-1/A filing)
• 333-278890 — Registration Number (SEC registration number for the offering)
• 50 Health Sciences Drive — Principal Executive Office Address (Stony Brook, New York 11790)
• 631-240-8800 — Business Phone Number (Registrant's contact number)

Key Players & Entities

• APPLIED DNA SCIENCES INC (company) — Registrant
• James A. Hayward, Ph.D., Sc.D. (person) — Chairman, Chief Executive Officer and President
• McDermott Will & Emery LLP (company) — Legal counsel
• Ellenoff Grossman & Schole LLP (company) — Legal counsel
• 333-278890 (registration_number) — Securities Act registration number

FAQ

Industry Context

Applied DNA Sciences operates in the testing laboratories sector, focusing on providing DNA-based solutions.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Monitor for the effectiveness of the registration statement and the commencement of the securities offering.
2. Analyze any subsequent amendments or filings for updated financial information and offering details.
3. Research the company's business model and market position to understand the context of the capital raise.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating ongoing efforts to register securities for public sale.

Key Financial Figures

• $0.001 — 2 shares of our common stock, par value $0.001 per share, together with Series A warra
• $3.08 — sumed combined public offering price of $3.08 per share and Series Warrants, which is
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
• $0.0001 — e of each pre-funded warrant will equal $0.0001 per share of common stock. For each pre
• $110,000 — t-of-pocket expenses in an amount up to $110,000. In addition, we have agreed to issue t

Filing Documents

• tm2412319d2_s1a.htm (S-1/A) — 503KB
• tm2412319d2_ex3-1.htm (EX-3.1) — 288KB
• tm2412319d2_ex4-14.htm (EX-4.14) — 102KB
• tm2412319d2_ex4-15.htm (EX-4.15) — 107KB
• tm2412319d2_ex4-16.htm (EX-4.16) — 107KB
• tm2412319d2_ex4-17.htm (EX-4.17) — 107KB
• tm2412319d2_ex5-1.htm (EX-5.1) — 20KB
• tm2412319d2_ex10-50.htm (EX-10.50) — 184KB
• tm2412319d2_ex10-51.htm (EX-10.51) — 21KB
• tm2412319d2_ex23-1.htm (EX-23.1) — 2KB
• tm2412319d2_ex-filingfees.htm (EX-FILING FEES) — 24KB
• tm2412319d1_s1img01.jpg (GRAPHIC) — 20KB
• tm2412319d1_s1img02.jpg (GRAPHIC) — 29KB
• tm2412319d2_ex5-1img01.jpg (GRAPHIC) — 4KB
• tm2412319d2_ex5-1img02.jpg (GRAPHIC) — 4KB
• 0001104659-24-061374.txt (&nbsp;) — 1545KB

Forward-Looking Statements

Forward-Looking Statements 2 Prospectus Summary 3 Summary of the Offering 11

Use of Proceeds

Use of Proceeds 16 Market Price of our Common Stock and Related Stockholder Matters 16 Capitalization 17

Description of Securities

Description of Securities 19 PLAN OF DISTRIBUTION 23 Experts 25 Legal Matters 25 Where you can find more information 26 MATERIAL CHANGES 26 Incorporation by Reference 26 ABOUT THIS PROSPECTUS The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus, or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any related free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any related free writing prospectus is delivered or securities are sold on a later date. We have not done anything that would permit this offering or possession or distribution of this pr

Forward-looking statements

Forward-looking statements may include our plans and objectives for future operations, including plans and objectives relating to our products and our future economic performance, projections, business strategy and timing and likelihood of success. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, demand for our products and services, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Any of the assumptions underlying the forward-looking statements contained in this prospectus could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward looking-statements contained herein. PROSPECTUS SUMMARY This summary highlights certain information about us, this offering and information appearing elsewhere in this prospectus and in the documents we incorporate by reference in this prospectus. This summary is not complete and does not contain all of the information that you should consider before investing in our securities. After you carefully read this summary, to fully understand our Company and this offering and its consequences to you, you should read this entire prospectus and any related free writing prospectus authorized by us, including the information referred to under the heading "Risk Factors" in this prospectus beginning on page 12, and any related free writing prospectus, as well as the o

View Full Filing

View this S-1/A filing on SEC EDGAR